Skip to content
Aisa Pharma - Channeling Therapies
  • Home
  • News
  • Publications
  • Careers
  • Contact
  • Home
  • News
  • Publications
  • Careers
  • Contact
  • AISA-021
    • About AISA-021
    • Development Pipeline
  • RECONNOITER Study
  • About Aisa Pharma
    • Our Company
    • Leadership
    • Directors
    • Consultants
    • Scientific Advisors
  • Investor Information
  • News
  • Careers
  • Contact Us
  • AISA-021
    • About AISA-021
    • Development Pipeline
  • RECONNOITER Study
  • About Aisa Pharma
    • Our Company
    • Leadership
    • Directors
    • Consultants
    • Scientific Advisors
  • Investor Information
  • News
  • Careers
  • Contact Us

Selected Publications

  • Cilnidipine impact on vascular remodeling in atherosclerosis (carotid intimal media thickening)
  • Possible mechanism for Cilnidipine improving VQ mismatch in fibrotic lung disease
  • Effect of Current calcium channel blockers on GI functioning in Systemic Sclerosis patients
  • Abnormal cold response is highly prevalent, especially with Raynaud's and might improve with cilnidipine treatment
  • Nifedipine is more antifibrotic than currently approved treatments for pulmonary fibrosis : An AI and In -Silica as well as Tissue Analysis
  • Pedal edema is decreased tenfold with cilnidipine versus amlodipine
  • Review article on cilnidipine
  • Arthritis Care Research - 2025 - Frech
  • RECONNOITER World Congress Abstract 3-3-2026

Copyright © 2021–2026 Aisa Pharma, Inc. All rights reserved.